<DOC>
	<DOC>NCT00455728</DOC>
	<brief_summary>This study is a multicenter, open label, observational, post marketing surveillance study of NutropinAq® in Austria, France, Germany, Italy, Spain, Romania and United Kingdom to collect long-term safety and effectiveness information on NutropinAq® during treatment of paediatric growth disorders.</brief_summary>
	<brief_title>A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders</brief_title>
	<detailed_description>The objective of this study is to collect long term safety and effectiveness information on Ipsen's growth hormone (GH) NutropinAq® regarding treatment of paediatric growth disorders for which GH is indicated.</detailed_description>
	<criteria>Children of either sex who are treated with NutropinAq® for the treatment of growth failure Patients who are willing to comply with followup appointments throughout study participation Written informed consent signed by both parents or by the liable parent or by the legal guardian when applicable, and by the child when applicable Patients not treated with NutropinAq® Patients with closed epiphyses Patients with active neoplasia</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>